Passage BIO (PASG) Current Assets (2019 - 2026)
Passage BIO (PASG) posted quarterly Current Assets of $34.7 million for Q1 2026, down 47.89% year-over-year from $66.7 million in Q1 2025, and down 27.26% quarter-over-quarter from $47.8 million in Q4 2025.
Passage BIO (PASG) Current Assets (2019 - 2026) Analysis & Trends
Passage BIO's Current Assets history runs 8 years deep, the most recent figure standing at $34.7 million for Q1 2026.
- In Q1 2026, Current Assets fell 47.89% year-over-year to $34.7 million; the TTM figure through Mar 2026 stood at $34.7 million (down 47.89% YoY), while the FY2025 annual figure was $47.8 million, down 39.4% from the prior year.
- Current Assets for Q1 2026 stood at $34.7 million, down from $47.8 million in the prior quarter.
- The five-year high for Current Assets was $283.0 million in Q1 2022, with the low at $34.7 million in Q1 2026.
- The 5-year median for Current Assets is $108.3 million (2024), against an average of $127.4 million.
- The sharpest annual moves came in 2024 and 2026: Current Assets sank 33.18% in 2024, then tumbled 47.89% in 2026.
- Passage BIO's Current Assets stood at $197.0 million in 2022, then plunged by 40.14% to $118.0 million in 2023, then tumbled by 33.18% to $78.8 million in 2024, then slumped by 39.4% to $47.8 million in 2025, then slipped by 27.26% to $34.7 million in 2026.
- Business Quant data shows PASG's Current Assets at $34.7 million in Q1 2026, $47.8 million in Q4 2025, and $55.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | Passage BIO | 13.96 Mn | 13.96 Mn | - | 25.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.18 Mn |
| Mar 31, 2026 | 34.74 Mn |
| Dec 31, 2025 | 47.76 Mn |
| Sep 30, 2025 | 55.73 Mn |
| Jun 30, 2025 | 60.32 Mn |
| Mar 31, 2025 | 66.67 Mn |
| Dec 31, 2024 | 78.82 Mn |
| Sep 30, 2024 | 87.22 Mn |
| Jun 30, 2024 | 95.00 Mn |
| Mar 31, 2024 | 108.29 Mn |
| Dec 31, 2023 | 117.96 Mn |
| Sep 30, 2023 | 135.71 Mn |
| Jun 30, 2023 | 153.63 Mn |
| Mar 31, 2023 | 171.62 Mn |
| Dec 31, 2022 | 197.04 Mn |
| Sep 30, 2022 | 222.52 Mn |
| Jun 30, 2022 | 250.58 Mn |
| Mar 31, 2022 | 283.00 Mn |
| Dec 31, 2021 | 325.07 Mn |
| Sep 30, 2021 | 366.47 Mn |